Literature DB >> 601857

The effect of chemo-immunotherapy with SDDS, pyrimethamine and anti-toxoplasma serum on toxoplasma gondii cysts in latent infected NMRI mice.

H Werner, K N Masihi, I Tischer, E Adusu.   

Abstract

A substantial reduction of brain cyst numbers could be obtained through a six week therapy with SDDS-pyrimethamine combination or a high titer anti-Toxoplasma serum. NMRI mice experimentally infected three months earlier with cyst-forming Toxoplasma strains Witting, Alt or Gail were used. The effectiveness of the treatments could be increased considerably by simultaneous administration of anti-Toxoplasma serum and SDDS-pyrimethamine. A highly significant reduction of brain cyst numbers, upto 65%, could be obtained by using this mode of chemoimmunotherapy. The effectiveness of the treatments used varied amongst the three Toxoplasma strains.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 601857

Source DB:  PubMed          Journal:  Tropenmed Parasitol        ISSN: 0303-4208


  4 in total

1.  In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.

Authors:  F G Araujo; J Huskinson-Mark; W E Gutteridge; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.

Authors:  F G Araujo; J Huskinson; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

3.  Immunization of NMRI mice against virulent Toxoplasma gondii. Differing efficacy of eleven cyst-forming Toxoplasma strains.

Authors:  K N Masihi; H Werner
Journal:  Z Parasitenkd       Date:  1977-12-29

Review 4.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.